Burney Co. Has $666,000 Stock Position in Zoetis Inc. (NYSE:ZTS)

Burney Co. lowered its position in Zoetis Inc. (NYSE:ZTSFree Report) by 3.0% in the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 3,831 shares of the company’s stock after selling 118 shares during the period. Burney Co.’s holdings in Zoetis were worth $666,000 as of its most recent SEC filing.

Other large investors have also made changes to their positions in the company. Evermay Wealth Management LLC increased its position in shares of Zoetis by 439.3% in the 1st quarter. Evermay Wealth Management LLC now owns 151 shares of the company’s stock valued at $25,000 after buying an additional 123 shares in the last quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC increased its position in shares of Zoetis by 430.8% in the 1st quarter. Nelson Van Denburg & Campbell Wealth Management Group LLC now owns 138 shares of the company’s stock valued at $26,000 after buying an additional 112 shares in the last quarter. Worth Asset Management LLC bought a new stake in shares of Zoetis in the 1st quarter valued at $26,000. VisionPoint Advisory Group LLC bought a new position in Zoetis during the 2nd quarter worth about $29,000. Finally, Moisand Fitzgerald Tamayo LLC increased its holdings in Zoetis by 105.5% during the 3rd quarter. Moisand Fitzgerald Tamayo LLC now owns 187 shares of the company’s stock worth $33,000 after purchasing an additional 96 shares in the last quarter. Institutional investors own 89.47% of the company’s stock.

Analysts Set New Price Targets

ZTS has been the subject of a number of research reports. Piper Sandler increased their target price on Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a report on Monday, November 6th. Jefferies Financial Group reiterated a “buy” rating and set a $230.00 target price on shares of Zoetis in a report on Tuesday, December 19th. The Goldman Sachs Group increased their target price on Zoetis from $190.00 to $226.00 and gave the stock a “buy” rating in a report on Wednesday, January 17th. BNP Paribas initiated coverage on Zoetis in a report on Thursday, December 7th. They set an “outperform” rating and a $237.00 target price for the company. Finally, StockNews.com cut Zoetis from a “strong-buy” rating to a “buy” rating in a report on Thursday, February 1st. Nine analysts have rated the stock with a buy rating, According to MarketBeat.com, the company currently has an average rating of “Buy” and an average price target of $223.78.

Get Our Latest Stock Analysis on ZTS

Zoetis Stock Up 0.8 %

Shares of ZTS opened at $197.32 on Friday. Zoetis Inc. has a 12 month low of $151.03 and a 12 month high of $201.92. The firm’s 50 day moving average is $192.81 and its 200-day moving average is $183.12. The stock has a market capitalization of $90.59 billion, a PE ratio of 40.11, a P/E/G ratio of 2.87 and a beta of 0.88. The company has a current ratio of 3.87, a quick ratio of 2.16 and a debt-to-equity ratio of 1.29.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 4th. Stockholders of record on Friday, April 19th will be issued a dividend of $0.432 per share. The ex-dividend date of this dividend is Thursday, April 18th. This represents a $1.73 annualized dividend and a dividend yield of 0.88%. Zoetis’s dividend payout ratio is presently 35.16%.

Insider Transactions at Zoetis

In related news, CEO Kristin C. Peck sold 13,000 shares of Zoetis stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $176.84, for a total value of $2,298,920.00. Following the transaction, the chief executive officer now directly owns 56,843 shares of the company’s stock, valued at $10,052,116.12. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Zoetis news, EVP Roxanne Lagano sold 923 shares of the firm’s stock in a transaction that occurred on Friday, November 17th. The shares were sold at an average price of $177.46, for a total value of $163,795.58. Following the sale, the executive vice president now owns 22,665 shares in the company, valued at $4,022,130.90. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Kristin C. Peck sold 13,000 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The shares were sold at an average price of $176.84, for a total transaction of $2,298,920.00. Following the completion of the sale, the chief executive officer now owns 56,843 shares in the company, valued at approximately $10,052,116.12. The disclosure for this sale can be found here. Over the last ninety days, insiders have sold 17,346 shares of company stock valued at $3,139,405. 0.12% of the stock is currently owned by company insiders.

Zoetis Profile

(Free Report)

Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.

Featured Stories

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTSFree Report).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.